| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
2024 Annual Report
|
30 Sep 2024 2:42PM |
$0.012 |
$0.013 |
risen by
8.33%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
$400,000 R&D TAX INCENTIVE LOAN FACILITY
|
11 Sep 2024 11:28AM |
$0.015 |
$0.013 |
fallen by
13.33%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Change of principal place of business
|
10 Sep 2024 5:35PM |
$0.015 |
$0.013 |
fallen by
13.33%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Preliminary Final Report
|
30 Aug 2024 2:55PM |
$0.016 |
$0.013 |
fallen by
18.75%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- HitIQ Limited released its Preliminary Final Report for the year ended 30 June 2023.
- The company reported a significant increase in revenue, driven primarily by sales of its concussion management technologies.
- Net loss for the year was reduced compared to the previous year, showing improved management of expenses.
- The report highlights key operational achievements, including new partnerships and expansion into international markets.
- Research and development expenses increased as the company continues to innovate in its product offerings.
- Future outlook includes further international expansion and development of new concussion management solutions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Second US Patent Approved for Nexus Technology
|
21 Aug 2024 9:25AM |
$0.019 |
$0.013 |
fallen by
31.58%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Second US Patent Approved for Nexus™ Technology
- US Patent Application US 17/427,869 approved
- IP portfolio bolstered by second US patent
- Flexible PCB design to ensure a 'one size fits all' functionality
- Technology enables fitting instrumented components to various mouthguard shapes and sizes
- Patent aims to transition instrumented mouthguard technology from research tools to commercial use
- Chief Executive, Mike Vegar, emphasizes the importance of the patent in ensuring functionality, comfort, and manufacturing efficiency
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Notification of cessation of securities - HIQ
|
19 Aug 2024 1:14PM |
$0.018 |
$0.013 |
fallen by
27.78%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Agreement Signed with Australia's Premier Sports High School
|
19 Aug 2024 10:52AM |
$0.017 |
$0.013 |
fallen by
23.53%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- HITIQ Limited signs a 2-year agreement with Westfield Sports High School.
- Provision of HITIQ’s instrumented mouthguards and CSX app included in the agreement.
- Westfield Sports High School is recognized as Australia’s leading sports high school.
- This marks HITIQ's first entry into the school sports market.
- The agreement aims to monitor and manage head impacts among student-athletes.
- The deal emphasizes HITIQ's technology scalability across different sports participation levels.
- School Principal Andrew Rogers cites commitment to player safety and support.
- HITIQ’s Chief Commercial Officer, Damien Hawes, highlights the significance of the partnership.
- HITIQ's technology includes the Nexus™ mouthguard and CSX concussion management platform.
- The partnership sets a new standard for head injury surveillance and management in school sports.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Pause in Trading
|
19 Aug 2024 9:56AM |
$0.017 |
$0.013 |
fallen by
23.53%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading in HitIQ Limited (Security Code: HIQ) temporarily paused.
- Pause pending further announcement.
- Announcement date: 19/08/2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Jun24 Quarterly Activities Statement and Appendix 4C
|
31 Jul 2024 5:28PM |
$0.016 |
$0.013 |
fallen by
18.75%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- US Patent Approval for Nexus™ Technology
- World Rugby Performance Specification Achieved
- NRL Women teams deployed with Nexus™
- Updated concussion management protocol, SCAT6, deployed
- Signed $1.6m convertible note facility with Harmil Angel Investments
- Cash reserves of A$576k as of 30 June 2024
- Payments to related parties totaling A$54,776
- Corporate appointment of Henslow and Earl Eddings
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
US Patent Approved for Nexus Technology
|
30 Jul 2024 10:39AM |
$0.016 |
$0.013 |
fallen by
18.75%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- US Patent Application US 17/753,356 approved
- HITIQ technology now supported by foundational IP protection in key jurisdiction
- Data categorization key aspect of IP related to field performance of technology
- Data categorization enables delivery of reliable field data
- Patent neutralizes noisy field environments and false positive data
- Patent unlocks commercial opportunities in the key target market
- Approval validates technology and secures major market entry
- Technology involves a custom calibrated mouthguard with impact sensors
- Legal announcement authorized by HITIQ Board of Directors
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
HITIQ Mouthguard Technology Meets World Rugby Specification
|
18 Jul 2024 9:42AM |
$0.017 |
$0.013 |
fallen by
23.53%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- HitIQ meets World Rugby specification for instrumented mouthguards
- Approval enables use in global rugby union
- Target market opportunity spans 132 national member federations
- Technology enhances player safety via real-time data for head impact
- Commercial opportunities expected to rise from this approval
- HitIQ's Nexus™ mouthguard embedded with validated impact sensor technology
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Change of Director's Interest Notice - Phil Carulli
|
11 Jun 2024 3:34PM |
$0.023 |
$0.013 |
fallen by
43.48%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Notification regarding unquoted securities - HIQ
|
21 May 2024 11:30AM |
$0.020 |
$0.013 |
fallen by
35%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Convertible Note and Appointment of Advisors
|
20 May 2024 10:04AM |
$0.016 |
$0.013 |
fallen by
18.75%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- HitIQ Limited announces the execution of a binding agreement for a Convertible Note to raise up to $1.5 million.
- The Convertible Note will be used to fund working capital and business growth initiatives.
- PAC Partners and KG Capital appointed as corporate advisors to assist with capital management and strategic initiatives.
- The Convertible Note includes terms such as conversion rights, interest rate, and maturity date.
- Funds raised will support commercial growth, partnerships, and product development.
- Company provides an update on its current cash position and financial outlook.
- Focus remains on achieving financial sustainability and operational growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Mar24 Quarterly Activities Statement and Appendix 4C
|
30 Apr 2024 6:14PM |
$0.026 |
$0.013 |
fallen by
50%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from operating activities increased to $0.46m in the March 2024 quarter, up from $0.36m in the December 2023 quarter.
- Secured new contracts and renewals with major sporting organizations and healthcare institutions.
- Launched new concussion management products and expanded into additional sports and healthcare markets.
- Maintained strong cash position with a balance of $4.5m at the end of the quarter.
- Demonstrated prudent cost control and operational efficiencies.
- Healthcare segment showed early traction, with new customer wins and growing interest.
- Focus remains on commercializing core technologies and scaling sales, particularly in the healthcare sector.
- Key priorities for the next quarter include further product rollouts, expanding market reach, and continued financial discipline.
- No payments were made to related parties during the quarter except for director fees and salaries.
- Outlook remains positive, with expected continued growth in revenue and customer base across core markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Notification of cessation of securities - HIQ
|
10 Apr 2024 2:36PM |
$0.029 |
$0.013 |
fallen by
55.17%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
HITIQ Granted New Australian Patent
|
4 Apr 2024 10:42AM |
$0.028 |
$0.013 |
fallen by
53.57%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- HitIQ Limited (ASX: HIQ) has been granted a new Australian patent.
- The patent is for a method and system for detecting and monitoring brain injuries using sensor technology.
- The newly granted patent extends coverage for HitIQ’s core technology in Australia.
- The technology supports HitIQ’s existing product portfolio including the Nexus A9 mouthguard.
- This patent further strengthens HitIQ’s intellectual property protection and commercialisation potential.
- The news is seen as significant for the company’s position in sports technology and injury management.
- HitIQ’s CEO has commented that the patent grant is validation of their innovation and R&D efforts.
- The announcement highlights that HitIQ’s technology is used by professional and amateur sporting organisations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
NRL Adopt HITIQ Mouthguard Technology for 2024 Season
|
28 Mar 2024 11:49AM |
$0.025 |
$0.013 |
fallen by
48%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Notification of cessation of securities - HIQ
|
22 Mar 2024 4:32PM |
$0.024 |
$0.013 |
fallen by
45.83%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
R&D TAX INCENTIVE LOAN FACILITY
|
18 Mar 2024 3:14PM |
$0.025 |
$0.013 |
fallen by
48%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Half Yearly Report and Accounts
|
29 Feb 2024 1:01PM |
$0.026 |
$0.013 |
fallen by
50%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Report covers the half-year ended 31 December 2023.
- Principal activity is developing technology for head impact detection and monitoring in sports.
- Revenue increased modestly, but the company recorded a net loss.
- Ongoing investment in product development, sales, and marketing.
- Focus on international market expansion and operational scaling.
- Acknowledgement of risks including technology adoption, competition, and funding requirements.
- Emphasis on new strategic partnerships and ongoing business development.
- Management remains confident in achieving long-term growth despite short-term losses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Initial Director's Interest Notice - James Barrie
|
23 Feb 2024 4:26PM |
$0.026 |
$0.013 |
fallen by
50%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
Final Director's Interest Notice - Glenn Smith
|
23 Feb 2024 4:25PM |
$0.026 |
$0.013 |
fallen by
50%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
CLOSE OF SHORTFALL OFFER AND LEADERSHIP CHANGES
|
23 Feb 2024 3:48PM |
$0.026 |
$0.013 |
fallen by
50%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$10 |
UK SPORTS INSTITUTE SIGNS LANDMARK DEAL WITH HITIQ
|
20 Feb 2024 9:38AM |
$0.021 |
$0.013 |
fallen by
38.10%
|
|
Call 1300 880 160
Start a chat
Schedule a call
